WO2001046455A3 - Survivin promotion of angiogenesis - Google Patents

Survivin promotion of angiogenesis Download PDF

Info

Publication number
WO2001046455A3
WO2001046455A3 PCT/US2000/034663 US0034663W WO0146455A3 WO 2001046455 A3 WO2001046455 A3 WO 2001046455A3 US 0034663 W US0034663 W US 0034663W WO 0146455 A3 WO0146455 A3 WO 0146455A3
Authority
WO
WIPO (PCT)
Prior art keywords
survivin
angiogenesis
promotion
expression
agents
Prior art date
Application number
PCT/US2000/034663
Other languages
French (fr)
Other versions
WO2001046455A2 (en
Inventor
Dario C Altieri
William C Sessa
Original Assignee
Univ Yale
Dario C Altieri
William C Sessa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Dario C Altieri, William C Sessa filed Critical Univ Yale
Priority to CA002393646A priority Critical patent/CA2393646A1/en
Priority to JP2001546951A priority patent/JP2003529554A/en
Priority to MXPA02006167A priority patent/MXPA02006167A/en
Priority to AU27308/01A priority patent/AU2730801A/en
Priority to EP00990262A priority patent/EP1242050A4/en
Publication of WO2001046455A2 publication Critical patent/WO2001046455A2/en
Publication of WO2001046455A3 publication Critical patent/WO2001046455A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses methods for promoting angiogenesis using agents that increase the activity function and/or expression of survivin. The present invention also discloses methods for inhibiting angiogenesis using agents that inhibit activity, the function and/or expression of survivin.
PCT/US2000/034663 1999-12-21 2000-12-21 Survivin promotion of angiogenesis WO2001046455A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002393646A CA2393646A1 (en) 1999-12-21 2000-12-21 Survivin promotion of angiogenesis
JP2001546951A JP2003529554A (en) 1999-12-21 2000-12-21 Survivin promotes angiogenesis
MXPA02006167A MXPA02006167A (en) 1999-12-21 2000-12-21 Survivin promotion of angiogenesis.
AU27308/01A AU2730801A (en) 1999-12-21 2000-12-21 Survivin promotion of angiogenesis
EP00990262A EP1242050A4 (en) 1999-12-21 2000-12-21 Survivin promotion of angiogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17299199P 1999-12-21 1999-12-21
US60/172,991 1999-12-21

Publications (2)

Publication Number Publication Date
WO2001046455A2 WO2001046455A2 (en) 2001-06-28
WO2001046455A3 true WO2001046455A3 (en) 2002-05-10

Family

ID=22630045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034663 WO2001046455A2 (en) 1999-12-21 2000-12-21 Survivin promotion of angiogenesis

Country Status (6)

Country Link
EP (1) EP1242050A4 (en)
JP (1) JP2003529554A (en)
AU (1) AU2730801A (en)
CA (1) CA2393646A1 (en)
MX (1) MXPA02006167A (en)
WO (1) WO2001046455A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7534773B1 (en) 1999-02-26 2009-05-19 The University Of British Columbia TRPM-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2002007732A2 (en) * 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
EP1465995B1 (en) 2002-01-17 2008-07-30 The University of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
EP1530636B1 (en) 2002-08-21 2010-08-18 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
WO2004094606A2 (en) * 2003-04-18 2004-11-04 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
KR20070095882A (en) 2004-11-09 2007-10-01 산타리스 팔마 에이/에스 Lna oligonucleotides and the treatment of cancer
NZ584330A (en) * 2007-10-04 2013-01-25 Bionomics Ltd Markers of endothelial cells and uses thereof
FR2932086A1 (en) * 2008-06-06 2009-12-11 Lvmh Rech ANTI-AGE COSMETIC CARE METHOD BY STIMULATING THE EXPRESSION OF SURVIVAL
US10705008B2 (en) 2013-03-15 2020-07-07 Iris International, Inc. Autofocus systems and methods for particle analysis in blood samples
JP6831836B2 (en) 2015-09-04 2021-02-17 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． Anti-survivin antibody for cancer treatment

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AMBROSINI G. ET AL.: "Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting", J. BIOL. CHEM., vol. 273, no. 18, 1 May 1998 (1998-05-01), pages 11177 - 11182, XP002945209 *
BRANCH A.D.: "A good antisense molecule is hard to find", TIBS, vol. 23, February 1998 (1998-02-01), pages 45 - 50, XP002945210 *
ECK S.L. ET AL.: "Gene-based therapy. Goodman & Gilmans's: The pharmcological basis of therapeutics", 1996, MCGRAW-HILL, NY, XP002945211 *
O'CONNOR D.S. ET AL.: "Control of apoptosis during angiogenesis by survivin expression in endothelial cells", vol. 156, no. 2, February 2000 (2000-02-01), pages 393 - 398, XP002945208 *
PAPAPETROPOULOS A. ET AL.: "Angiopoietin-1 (Ang-1) is an inhibitor of endothelial cell apoptosis", GENERAL PHARMACOLOGY ABSTRACTS, vol. 34, April 2000 (2000-04-01), pages 293, XP002945214 *
PAPAPETROPOULOS A.: "Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway", J. BIOL. CHEM., vol. 275, no. 13, 31 March 2000 (2000-03-31), pages 9102 - 9105, XP002945212 *
See also references of EP1242050A4 *
TAMMI I. ET AL.: "IAP-family protein survivin inhibits caspase activity and apoptosis induced by fas (CD95), bax, caspases and anticancer drugs", CANCER RESEARCH, vol. 58, December 1998 (1998-12-01), pages 5315 - 5320, XP002945215 *
TRAN J. ET AL.: "Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 264, no. 3, November 1999 (1999-11-01), pages 781 - 788, XP002945213 *

Also Published As

Publication number Publication date
CA2393646A1 (en) 2001-06-28
EP1242050A4 (en) 2004-05-26
EP1242050A2 (en) 2002-09-25
WO2001046455A2 (en) 2001-06-28
AU2730801A (en) 2001-07-03
JP2003529554A (en) 2003-10-07
MXPA02006167A (en) 2004-02-26

Similar Documents

Publication Publication Date Title
LUC00074I2 (en) Method for controlling the activity of immunologically functional molecule
AUPQ798800A0 (en) Support of loads from garments, carry-packs or the like
WO1999057325A3 (en) Enzymes mixture
HK1043795A1 (en) Substituted bicyclic derivatives useful as anticancer agents.
HK1048122A1 (en) Method for the preparation of citalopram.
WO2001019992A3 (en) FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES
ZA200108855B (en) Method for the preparation of citalopram.
WO1999054326A8 (en) Dihydropyrimidines
WO1998040055A3 (en) Anti-epileptogenic agents
ZA200108854B (en) Method for the preparation of citalopram.
WO2001046455A3 (en) Survivin promotion of angiogenesis
WO2002092122A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
ZA987057B (en) 2-benzoylcyclohexane-1,3-diones.
WO1995006764A3 (en) Oligonucleotides with rna cleavage activity
ZA982568B (en) The specificity of gene expression.
ZA98755B (en) Substituted hydroxy-anilino derivatives of cyclobutane-3,4-diones.
HK1048318A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors.
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
NO985002D0 (en) Reception procedure as well as recipient
WO1998046632A3 (en) Inhibitors for urokinase receptor
CY2362B1 (en) Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis.
ZA988B (en) 3-aminocarbonyl-/3-aminothiocarbonyl-substituted 2-benzoylcyclohexane-1,3-diones.
ZA986B (en) Substituted 2-benzoylcyclohexane-1,3-diones.
ZA9810842B (en) Epoxidation catalyst, its use and epoxidation process in the presence of this catalyst.
WO2002032445A3 (en) Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000990262

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2393646

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/006167

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 546951

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000990262

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000990262

Country of ref document: EP